Yap

What Yap does

Yap Inc. is a Tokyo-based pharmaceutical and consumer-health services company founded in March 2023 that connects Japan's healthcare and OTC/supplement markets with international producers and brands. The company organizes its offering around three business lines: Care Link (a cloud platform for specialty pharmaceutical last-mile delivery), Global Bridge (two-way import/export services for pharmaceuticals, raw materials, and consumer health products), and Garden (supplement OEM/ODM development at GMP-certified domestic facilities). It serves specialty pharmaceutical manufacturers, Japanese self-pay clinics, domestic pharmaceutical manufacturers seeking overseas APIs and raw materials, overseas pharma companies seeking Japan entry, and Japanese OTC/supplement brands seeking international expansion, alongside retailers and e-commerce channels for distributed consumer health products including Press Shot and GOLI.

The technical core is Yap Care Link, a cloud-based platform composed of a pharmacy dashboard, logistics management module, and patient-facing mobile application with delivery tracking, medication check-ins, and chat functionality, designed for cold-chain compliant last-mile delivery of specialty pharmaceuticals and integration with Patient Support Programs. Revenue is generated through a mix of pricing models: SaaS/platform or transaction fees for Care Link (currently in Phase 1 PoC), transaction-based service fees for Global Bridge import/export work, professional services fees for Garden OEM/ODM development, and distribution margins from selling Press Shot and GOLI supplements to Japanese drugstores, retailers, clinics, and e-commerce partners. All service lines are quote-based, with cost depending on product type, scale, formulation, and quantity. The company's operating footprint spans 5+ countries (Japan, Bangladesh, India, Singapore, Indonesia) through a network of 7+ partners including UniMed, Holden Medical, Eurogen, Asa Ren, ONNURI JAPAN, and a domestic GMP manufacturing partner.

Yap was founded by Masaya Yamamoto, a CEO with over 25 years of pharmaceutical industry experience including cloud migration and RPA implementation programs. The company is venture-backed by Antler Japan (pre-seed, May 2023, ¥37M) and Nissay Capital (seed, February 2024). Within its first year, Yap supported the entry of UniMed UniHealth into Japan — the first Bangladeshi pharmaceutical company to ever enter the Japanese market — and subsequently added an Indonesia digital biobank collaboration with Asa Ren and consumer health distribution for Press Shot and GOLI. The firm is currently preparing the Phase 1 proof-of-concept rollout of Yap Care Link.

Name

Yap

Legal name

Yap株式会社

Website

https://yap.co.jp

Company type

Private

Founded year

2023

Operating status

Operating

Headcount range

1–10 employees

Short description

Yap Inc. is a Tokyo-based pharmaceutical services company operating Yap Care Link (specialty pharma last-mile delivery), Global Bridge (Japan inbound/outbound pharma import-export), and Garden (supplement OEM/ODM) for foreign pharma firms, clinics, manufacturers, and Japanese OTC brands.

Ownership category

akta.pro rank

Product category

Pharmaceutical Distribution Services

NAICS

Drugs and Druggists' Sundries Merchant Wholesalers (424210), Support Activities for Transportation (488), Packaging and Labeling Services (56191)

SIC

Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)

akta.pro primary industry

Third-Party Logistics (3PL) & Warehousing for Pharmaceuticals (HLAIAJAL)

akta.pro secondary industries

Pharmaceuticals & Biopharma (TLAIALAC), Pharmaceuticals & Life Sciences Forwarding (GxP/GDP) (TLACAJAB), Pharmaceutical & Medical Device Packaging (GMP, Tamper-Evident, Cold-Chain Packs) (TLAIAGAI), Clinical Trials & Investigational Product (IP) Cold Chain Logistics (TLAIAIAC)

Keywords

• Pharmaceutical distribution services
• Specialty pharma last-mile delivery
• Cold-chain logistics platform
• Pharmaceutical import export
• Supplement OEM ODM development

Headquarters

HQ city

Tokyo

HQ country

Japan

HQ region

Asia

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales, Supply Chain

Revenue model

1. Yap-cloud Platform (Specialty Pharma Distribution): SaaS/platform fees or transaction-based fees for pharmacy-to-patient last-mile delivery of specialty pharmaceuticals. Currently in Phase 1 PoC; revenue model to be confirmed at scale.
2. Global Bridge — Import & Export Services: Fees for regulatory navigation, import licensing, customs clearance, and domestic logistics for overseas pharma products entering Japan and Japanese products expanding globally. Revenue derived from import/export service fees and potentially distribution margins.
3. Supplement OEM/ODM (Garden): Fees for end-to-end supplement and health food development — from planning and formulation to GMP-certified manufacturing, packaging, brand design, and export documentation. Revenue from OEM/ODM service fees and manufacturing coordination.
4. Product Distribution (Press Shot, GOLI): Distribution and sales partnership revenues from distributing functional OTC supplements (Press Shot, GOLI) to Japanese retailers, drugstores, clinics, and e-commerce businesses. Yap acts as sales partner/distributor.

Pricing tiers

Go-to-market motion3 records

Distribution channels5 records

Marketing channels5 records

Core offering

Yap operates a three-door pharmaceutical and health industry hub: (1) Yap Care Link cloud platform provides pharmacy-to-patient last-mile delivery for specialty pharmaceuticals with cold-chain management, adherence monitoring, and PSP integration; (2) Global Bridge offers two-way import/export services between Japan and global markets, handling regulatory navigation, customs clearance, and domestic logistics for overseas pharma entering Japan and Japanese OTC/supplements going abroad; (3) Garden provides made-in-Japan supplement and health-food OEM/ODM development through GMP-certified manufacturing partners, coordinated end-to-end in English.

Product overview

Yap operates as a pharmaceutical and health industry hub with three interconnected business doors: (1) Care Link — featuring Yap Care Link cloud platform for specialty pharmaceutical last-mile delivery from pharmacies to patient homes; (2) Global Bridge — import/export services for pharmaceuticals and raw materials between Japan and international markets; and (3) Garden — supplement OEM/ODM development plus distributed supplement products (Press Shot functional health shots and GOLI vegan ACV gummies). The company provides end-to-end solutions from regulatory navigation to logistics, serving pharmaceutical companies, clinics, manufacturers, and retailers.

Differentiator

Problem solved

Functional benefit

Products and services

• Yap Care Link Cloud-based specialty pharmaceutical last-mile delivery platform connecting pharmacies to patient homes, featuring pharmacy dashboard, logistics management, and a patient app with delivery tracking, medication check-ins, and chat functionality; addresses cold-chain management and treatment adherence monitoring for pharmaceutical companies.
• Global Bridge – Import Support Two-way bridge service that imports overseas pharmaceuticals, finished products, and raw materials into Japan, handling regulatory navigation (薬機法), import licensing, customs clearance, and domestic logistics end-to-end for self-pay clinics and Japanese pharmaceutical manufacturers.
• Global Bridge – Export Support Export service taking Japanese OTC pharmaceuticals, supplements, cosmetics, and raw materials into overseas markets, providing regulatory support, export documentation, and access to Yap's local partner network (UniMed Bangladesh, Holden Medical India, Eurogen Singapore).
• Garden – Supplement OEM/ODM Development End-to-end original supplement and health-food development service through Yap's domestic GMP-certified manufacturing partners, providing OEM/ODM development, raw material sourcing, packaging, brand design, and marketing support, coordinated entirely in English for international clinics, brands, and distributors.
• Press Shot Functional health-shot (liquid format) containing 11 amino acids, B vitamins, vitamin D, and zinc, with a cap-press and 10-second shake mixing mechanism that keeps ingredients fresh until consumption. Distributed by Yap across Japanese drugstores, retailers, clinics, and e-commerce channels with cumulative sales of 7.5 million bottles from Feb 2022 to Feb 2024.
• GOLI World's first vegan apple-cider-vinegar gummy supplement, made with tapioca starch in a pectin-based formulation free of gelatin and gluten, certified Kosher, Clean Label Project, B Corp, and Vegan. Distributed by Yap in Japan with major retail presence in the US (Target #2, Costco #2, Walmart #4, iHerb #4) and Korea (Olive Young full chain, TV shopping sell-outs).

Quantifiable outcome

• 48.7 drug shortage cases per pharmacy per month — indicating the scale of the supply chain problem Yap-cloud addresses
• +5 more outcomes

Named customers4 records

Segments6 records

Ideal customer profiles6 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration3 records

Feature4 records

Partnerships

Seven partnerships are on record, tiered core, flagship and minor.

• Asa Ren (Indonesia)coreStrategic or Co-development Partner · 1 February 2024Business alliance agreement signed February 2024 for digital biobank collaboration. Expands Yap's digital health and data ecosystem capabilities in the Southeast Asian market.
• UniMed UniHealth (Bangladesh)flagshipStrategic or Co-development Partner · 1 July 2023MoU signed July 2023, followed by import master contract in December 2023. Yap supported UniMed UniHealth — the first Bangladeshi pharmaceutical company ever to enter the Japanese market — providing end-to-end regulatory navigation, import licensing, customs clearance, and domestic logistics. Strategic first-mover partnership establishing Yap's Japan market-entry capability.
• Holden Medical (India)coreChannel Partner/ Reseller/ DistributorOfficial partner for distributing Japanese OTC pharmaceuticals, supplements, cosmetics, and raw materials in the Indian market. Part of Yap's global expansion partner network.
• Eurogen (Singapore)coreChannel Partner/ Reseller/ DistributorOfficial partner for distributing Japanese OTC pharmaceuticals, supplements, cosmetics, and raw materials in the Singapore market. Part of Yap's global expansion partner network.
• Domestic GMP Manufacturing PartnercoreStrategic or Co-development PartnerSpecialized domestic contract manufacturer of functional foods and supplements with GMP-certified facilities. Handles ingredient analysis and quality control. Yap coordinates the entire supplement development journey — from planning and formulation to manufacturing and export documentation — in English on behalf of clients. Partner name disclosed in business discussions.
• UniMed (Bangladesh)coreChannel Partner/ Reseller/ DistributorOfficial partner for distributing Japanese OTC pharmaceuticals, supplements, cosmetics, and raw materials in the Bangladesh market. Confirmed as official partner in the export partner network.
• ONNURI JAPAN Co., Ltd.minorChannel Partner/ Reseller/ DistributorImported and distributed by ONNURI JAPAN Co., Ltd. (Shinjuku-ku, Tokyo). Yap acts as distribution/sales partner for GOLI and Press Shot products in Japan. ONNURI JAPAN handles the importer/distributor role while Yap provides sales support.

Scale indicators6 records

Recent moves6 records

Expansion highlights6 records

Regional players

• Yusen Logistics: Japan-headquartered global logistics provider with dedicated healthcare/pharma capabilities including temperature-controlled transport. Comparable as a Japan-based 3PL with established pharma customers that could compete with Yap in import/export and last-mile pharma logistics.

Direct peers

• Marken (UPS Healthcare): UPS-owned specialty logistics provider with deep cold-chain pharma capabilities and direct-to-patient services. Direct comparable for Yap Care Link's last-mile specialty pharma delivery and treatment adherence monitoring features.
• World Courier (Cencora): Global specialty logistics provider (now part of Cencora/Alloga) focused on cold-chain pharmaceutical and biopharma distribution. Direct comparable to Yap Care Link's cold-chain specialty pharma last-mile thesis, though at global rather than Japan-domestic scale.
• Movianto: European pharmaceutical warehousing and distribution specialist with temperature-controlled storage and last-mile delivery. Comparable as a dedicated pharma distribution specialist against Yap Care Link's niche focus.
• CMIC Group: Japan's largest CRO and pharma services group offering regulatory support, clinical development, and market entry services. Comparable as a Japan-headquartered pharma BPO and regulatory services platform serving overseas pharma entering Japan.
• EPS Holdings: Japanese pharma services group (CRO, SMO, CDMO, and consulting). Comparable to Yap's Global Bridge business as a Japan-headquartered service provider helping overseas pharma and biotech navigate the Japanese market.

Broad incumbents

• Alfresa Holdings: Top-tier Japanese pharmaceutical wholesaler with growing focus on specialty pharmaceuticals and healthcare services. Comparable to Yap as a competitor for specialty pharma distribution and Patient Support Programs (PSP) business.
• Medipal Holdings: Japan's largest pharmaceutical wholesaler with nationwide distribution, healthcare-related BPO, and increasingly digital services. Comparable as the dominant incumbent in Japanese pharma distribution against which Yap's niche import/export and last-mile ambitions must compete.
• Suzuken / Mediceo: Major Japanese pharma wholesaler group (Suzuken + Mediceo + others) with extensive pharmacy coverage and specialty pharma distribution capabilities. Represents the established channel through which most specialty pharmaceuticals reach Japanese patients today.
• DHL Supply Chain (Life Sciences & Healthcare): Global 3PL with extensive life sciences and healthcare logistics capabilities, including cold chain and specialty pharma. Comparable as a broad incumbent offering overlapping logistics capabilities to Yap Care Link.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/yap-ddm

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds2 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Yap